BioPharmica has established the 100% owned entity, Molecular Discovery Systems (ABN 42 118 494 492) to acquire high content information from large scale sample analysis to create a range of direct and indirect commercial opportunities. Research and development is focused on theragnostic discovery and validation linking therapeutics and diagnostics.

We are located at Western Australian Institute for Medical Research:

Find out more on http://www.biopharmica.com.au/company.html

To view announcements via the Australian Stock Exchange click here asx.com.au.